A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease. Physostigmine Study Group

Neurology
L J ThalA Goldberg

Abstract

A multicenter trial to evaluate the efficacy of controlled-release physostigmine salicylate, a cholinesterase inhibitor, was conducted in 1,111 mild-to-moderate Alzheimer's disease (AD) subjects. During dose titration, subjects received 18, 24, or 30 mg of physostigmine or placebo daily. After a 2-week washout period, 366 subjects with putative improvement were randomized to receive either placebo or their best dose of physostigmine in a 6-week double-blind trial. Nonresponding patients (439) were randomized to receive in a separate double-blind trial either placebo or their highest tolerated dose of physostigmine. The primary efficacy measures included the cognitive subscale of the Alzheimer Disease Assessment Scale (ADAS) and a Clinical Global Impression of Change (CGIC). Secondary measures included the Mini-Mental State Examination and two activities-of-daily-living scales. At the end of the 6-week double-blind phase, physostigmine-treated patients scored 1.75 points higher than placebo-treated patients on the ADAS (p = 0.003) and 0.26 points higher on the CGIC (p = 0.012) in the intent-to-treat analysis. There was no significant improvement on the secondary outcome measures. Patients failing to respond to physostigmine duri...Continue Reading

Citations

Jun 4, 1999·Trends in Neurosciences·E PerryR Perry
May 4, 2000·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·S L RogersJ R Ieni
Sep 22, 1999·European Journal of Biochemistry·D GrisaruH Soreq
Nov 26, 1999·The New England Journal of Medicine·R Mayeux, M Sano
Mar 10, 2001·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·W Pryse-PhillipsJ Feightner
Oct 19, 2001·Journal of Neurology, Neurosurgery, and Psychiatry·K RockwoodD Wilkinson
Apr 20, 2004·Journal of Neurology, Neurosurgery, and Psychiatry·K Rockwood
Jan 1, 1998·International Journal of Psychiatry in Clinical Practice·M Rainer, H A Mucke
Nov 4, 2000·Expert Opinion on Investigational Drugs·J J Sramek, N R Cutler
Jul 29, 2000·Drug Development and Industrial Pharmacy·J L ChenC H Chiang
Apr 13, 2013·Progress in Neurobiology·S GauthierP Rosa-Neto
Mar 4, 2003·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·Ravi AnandStephen M Graham
Jul 9, 2009·European Journal of Oral Sciences·Nina KhosravaniJörgen Ekström
Nov 19, 2013·The Journal of Pharmacy and Pharmacology·Eduardo Luis KonrathAmélia T Henriques
Apr 17, 2014·Clinical Toxicology : the Official Journal of the American Academy of Clinical Toxicology and European Association of Poisons Centres and Clinical Toxicologists·F M GarlichL S Nelson
Oct 20, 1998·Journal of the American Geriatrics Society·P M Doraiswamy, D C Steffens
May 20, 1999·The Annals of Pharmacotherapy·W J KrallN R Cutler
Aug 14, 1999·Journal of Geriatric Psychiatry and Neurology·B M McLendon, P M Doraiswamy
Sep 5, 2012·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Hemant KumarDong-Kug Choi
Mar 16, 2001·Expert Opinion on Pharmacotherapy·D G Wilkinson
Jun 19, 2001·The Cochrane Database of Systematic Reviews·F Coelho, J Birks
Aug 24, 2018·Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco·Justin L HoskinMarwan Noel Sabbagh
May 17, 2001·Current Psychiatry Reports·E J DalyP Brown

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anorexia Nervosa

Anorexia nervosa (AN) is a psychiatric condition characterized by severe weight loss and secondary problems associated with malnutrition. Here is the latest research on AN.

Related Papers

International journal for vitamin and nutrition research. Internationale Zeitschrift für Vitamin- und Ernährungsforschung. Journal international de vitaminologie et de nutrition
J J SmitA C Beynen
© 2021 Meta ULC. All rights reserved